A new peer reviewed research article has been published in PLOS ONE titled “Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk“. (click the link to read the full article)
The article compares two GlaxoSmithKline manufactured H1N1 swine flu vaccines, both of which used the AS03 adjuvant. Arepanrix, produced by GSK in Canada and Pandemrix produced by GSK in Europe.
The article concludes:
“This work identified 1) higher amounts of structurally altered viral NP* in Pandemrix than in Arepanrix, 2) detergent-induced antigenic changes of viral NP, that are recognized by antibodies from children with narcolepsy, and 3) increased antibody response to NP in association of DQB1*06:02 risk allele of narcolepsy. These findings provide a link between Pandemrix and narcolepsy. Although detailed mechanisms of Pandemrix in narcolepsy remain elusive, our results move the focus from adjuvant(s) onto the H1N1 viral proteins.”